April 2010

Tumor vaccines in 2010: need for integration.

Journal Citation

Cell Immunol. 2010;263(2):138-47.

Authors

Koos D, Josephs SF, Alexandrescu DT, Chan RC, Ramos F, Bogin V, Gammill V, Dasanu CA, De Necochea-Campion R, Riordan NH, Carrier E.

Abstract

Induction of tumor-specific immunity is an attractive approach to cancer therapy, however to date every major pivotal trial has resulted in failure. While the phenomena of tumor-mediated immune suppression has been known for decades, only recently have specific molecular pathways been elucidated, and for the first time, rationale means of intervening and observing results of intervention have been developed. In this review we describe major advances in our understanding of tumor escape from immunological pressure and provide some possible therapeutic scenarios for enhancement of efficacy in future cancer vaccine trials.

Embrace your opportunity for a brighter future today.

The Stem Cell Institute has integrated Intranasal MTF Therapy into its autism protocol:

  • MTF therapy features exosomes and over 300 beneficial molecules
  • Works in synergy with our stem cells
  • Offers anti-inflammatory and regenerative effects
  • Delivered in an easy-to-administer aerosol format via the nose
  • To discover more about MTF and its benefits, click here